雷贝拉唑三联疗法治疗消化性溃疡病的效果赵新辰天津市第四中心医院药剂科

The effect of rabeprazole triple therapy on peptic ulcer disease <br>Zhao Xinchen <br>, Department of Pharmacy, Tianjin Fourth Central Hospital, Tianjin 300140 <br><br><br>Abstract: Objective: To <br><br>explore the effect of rabeprazole triple therapy on peptic gastric ulcer disease. <br><br>Methods: <br>80 patients with peptic ulcer disease admitted to our hospital from January 2017 to January 2019 were selected as the research objects and divided into the omeprazole group (40 cases) and Rebe according to the computer random number table method Prazole group (40 cases). <br>The omeprazole group was treated with triple therapy, while the rabeprazole group was treated with triple therapy. The efficacy and safety of the two methods were analyzed. <br><br>Results: The <br><br>total effective rate of the rabeprazole group was higher than that of the omeprazole group, with a statistically significant difference (P 0.05). The clinical symptom score, serum interleukin-6, C-reactive protein, and tumor necrosis factor-α levels were lower than those in the omeprazole group, and there was a statistically significant difference (P 0.05). <br>There was no significant difference in the incidence of adverse reactions between the two groups after treatment, and the difference was not statistically significant (P 0.05). <br><br><br><br>Conclusion: <br><br>Rabeprazole triple therapy is more effective than omeprazole triple therapy in the treatment of peptic ulcer disease, and the clinical symptom score, serum interleukin-6, C-reactive protein, and tumor necrosis factor-α level ratio Omeprazole triple therapy is lower. Therefore, rabeprazole triple therapy has a better effect on peptic ulcer disease. <br><br>Keywords: peptic ulcer disease; rabeprazole; omeprazole; triple therapy; safety

The effect of reberazole triple therapy in treating peptic ulcer disease<br>Zhao Xinchen<br>Tianjin Fourth Central Hospital Pharmacy Department Tianjin 300140<br><br>Summary: Purpose:<br><br>The effect of reberazole triple therapy in the treatment of peptic stomach ulcer disease is discussed.<br><br>Method:<br>The 80 patients with peptic ulcer disease treated in our hospital between January 2017 and January 2019 were selected as the subjects of the study and divided into the omeprazole group (40 cases) and the reberazole group (40 cases) according to the computer random number table method.<br>The omeprazole group used triple therapy, while the reberazole group used triple therapy to analyze the efficacy and safety of the two methods.<br><br>Results:<br><br>The treatment of the reberazole group was generally more efficient than that of the omeprazole group, with statistical differences (P 0.05). Clinical symptoms, serum leurialine-6, C-reactive protein, tumor necrosis factor-α levels were lower than omeprazole group, with statistical differences (P 0.05).<br>There was no significant difference in the rate of adverse reactions after drug treatment between the two groups, and the difference was not statistically significant (P 0.05).<br><br>Conclusion:<br><br>Reberazole triple therapy is more efficient in the treatment of peptic ulcer disease than omeprazole triple therapy, and the clinical symptom points, serum white blood cell median-6, C-reactive protein, tumor necrosis factor-α levels are lower than omeprazole triple therapy. Therefore, the triple therapy of reberazole is more effective in treating peptic ulcer disease.<br><br>Keywords: peptic ulcer disease; reberazole; omeprazole; triple therapy; safety

Effect of rabeprazole triple therapy on peptic ulcer<br>Zhao Xinchen<br>Pharmacy Department of Tianjin Fourth Central Hospital Tianjin 300140<br>Abstract: Objective: To study the clinical effect of the two methods<br>Objective to investigate the effect of rabeprazole triple therapy in the treatment of peptic ulcer.<br>method:<br>From January 2017 to January 2019, 80 patients with peptic ulcer disease in our hospital were selected as the research objects, and were divided into omeprazole group (40 cases) and rabeprazole group (40 cases) according to the computer random number table method.<br>Omeprazole group was treated with triple therapy, while rabeprazole group was treated with triple therapy.<br>result:<br>The total effective rate of rabeprazole group was higher than that of omeprazole group (P 0.05). The clinical symptom score, serum interleukin-6, C-reactive protein and tumor necrosis factor - α levels in omeprazole group were lower than those in omeprazole group (P 0.05).<br>There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05).<br>Conclusion<br>The effective rate of rabeprazole triple therapy in the treatment of peptic ulcer disease was higher than that of omeprazole triple therapy, and the clinical symptom score, serum interleukin-6, C-reactive protein and tumor necrosis factor - α levels were lower than those of omeprazole triple therapy. Therefore, rabeprazole triple therapy in the treatment of peptic ulcer disease is better.<br>Key words: peptic ulcer disease; rabeprazole; Omeprazole; triple therapy; safety<br>